Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
Date:10/28/2008

Fourth Innovation Award for Abbott in Six Years Recognizes Breakthrough

Treatment for the Most Common Form of Heart Disease

ABBOTT PARK, Ill., Oct. 28 /PRNewswire/ -- Abbott today announced it has received a 2008 Chicago Innovation Award for its XIENCE V(TM) Everolimus Eluting Coronary Stent System. Based on the product's innovative design and strong clinical data, the next-generation drug eluting stent represents a significant advance in the treatment of coronary artery disease.

Abbott's XIENCE V stent was approved by the United States Food and Drug Administration (FDA) and launched in July 2008, providing a new treatment option for the nearly 13 million Americans with coronary artery disease, the leading cause of death for both men and women in the United States. Stents are designed to prop open an artery that has become clogged by plaque build-up and restore blood flow to the heart. A drug eluting stent releases a medication (everolimus, in the case of XIENCE V) in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is the only drug eluting stent to demonstrate superiority over the previous market-leading drug eluting stent in two randomized, pivotal clinical trials -- and XIENCE V has become the market-leading drug eluting stent in just three months since launch.

This is the fourth Chicago Innovation Award that Abbott has received in six years. Most recently, the company's m2000(TM) molecular diagnostic instrument in combination with the RealTime HIV-1 viral load test received the honor in 2007. In 2005, the company's PathVysion(TM) breast cancer test received the honor, and in 2003, HUMIRA(TM), the first human monoclonal antibody drug for rheumatoid arthritis, won the award.

"At Abbott, we are proud to be in the business of developing innovative treatments that improve and save lives," said Miles D. White, chairman and chief executive officer, Abbott. "Receivi
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
2. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
3. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
4. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
5. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
6. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
7. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
8. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
10. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
11. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 Selexis ... for biologic drug discovery and mammalian cell line development, ... CHO-Mplus Libraries ™ will be presented at the 10th ... being held, September 8 – 10, 2014 at the ... , The following abstract will be presented during ...
(Date:7/30/2014)... 30, 2014 With the accelerated ... personal health expenditure as well as the improved ... China diagnostic reagent industry has been developing quickly, ... In 2013, Chinese in vitro diagnostics market size ... from in vitro diagnostic reagents. , Read ...
(Date:7/30/2014)... 30, 2014 Vycom announces the addition ... designed to meet Factory Mutual (FM) 4910 fire propagation ... as wet benches, process tools, fume hoods, furniture and ... damage to semiconductor wafers used in electronic chip manufacturing. ... PVC solution with excellent workability and superior aesthetics. It ...
(Date:7/30/2014)... , July 30, 2014  Dyadic International, Inc. ... whose patented and proprietary technologies are used to ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... Thomas "Tom" Dubinski as Vice President and Chief ... the financial and information technology operations for Dyadic ...
Breaking Biology Technology:Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4
... markets, the trend in health care employment could be counted on ... bringing yearly growth up over 345,000.The MedZilla.com Employment Report analyzes the ... ... Seattle, WA (Vocus) December 3, 2008 -- The U.S. economy ...
... and HOUSTON, Dec. 2 Transgenomic,Inc. (OTC ... Inc. (OTC,Bulletin Board: PWRM) today announced that ... acquire exclusive rights for Power3 Medical,s Neurodegenerative,Biomarkers, ... Alzheimer,s,and Parkinson,s disease. Transgenomic plans to ...
... postmenopause , , MONTVALE, N.J., ... symptoms is a challenge for women experiencing menopause. OBG ... have recently published a supplement titled Vasomotor symptoms: Managing ... James McGregor, MD, CM and Lee P. Shulman, MD, discuss ...
Cached Biology Technology:The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 4
(Date:7/30/2014)... roughly 3,000 pieces is still in its infant stage. ... be of major significance. "Amazingly often, we are findingin ... amber that we found in Baltic amber," explained Bonn ... amber comes from the Baltic Sea region, which is ... are, e.g., the coastal regions of Mecklenburg, Poland and ...
(Date:7/30/2014)... scientists unveiled the first high-resolution map of the ... country of Per. The new and improved methodology ... change for future market-based carbon economies. The ... ecological diversity and it provides the critical input ... conservation, land use, and enforcement purposes. The technique ...
(Date:7/29/2014)... Bristol,s Nutrition and Behaviour Unit (NBU) has looked into ... meals. , The research, to be presented at the ... 2014) in Seattle, USA this week [29 July to ... was led by Professor Jeff Brunstrom, and is based ... of a Biotechnology and Biological Sciences Research Council (BBSRC) ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... OCT. 31, 2011 A highly renowned obstetrician, professor ... and diabetic women have a higher risk of becoming ... later in life, received the March of Dimes 2011 ... of maternal-fetal nutrition. , Patrick M. Catalano, ...
... has been mapped. Now, it,s on to proteins, a much ... millions of distinct protein molecules in our bodies. Many of ... A team led by Northwestern University chemical biologist Neil Kelleher ... identify thousands of protein molecules quickly. Many have been skeptical ...
... at Weill Cornell Medical College say they have taken an ... regeneration -- an advance that could effectively treat millions of ... issue of the journal Cell , the research team ... that trigger generation of new lung alveoli, the numerous, tiny, ...
Cached Biology News:March of Dimes honors researcher who linked maternal obesity to a baby's long-term health 2So many proteins, so much promise 2So many proteins, so much promise 3Lung regeneration closer to reality with new discovery by Weill Cornell Medical College researchers 2Lung regeneration closer to reality with new discovery by Weill Cornell Medical College researchers 3Lung regeneration closer to reality with new discovery by Weill Cornell Medical College researchers 4
...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Assay Diluent Trial Pack, 4 x 100 mL...
Biology Products: